Foyston Gordon & Payne Inc boosted its stake in shares of Novo Nordisk A/S (NYSE:NVO) by 49.7% during the third quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 171,472 shares of the company’s stock after purchasing an additional 56,941 shares during the quarter. Novo Nordisk A/S comprises 1.4% of Foyston Gordon & Payne Inc’s holdings, making the stock its 23rd largest holding. Foyston Gordon & Payne Inc’s holdings in Novo Nordisk A/S were worth $8,256,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

A number of other hedge funds also recently modified their holdings of NVO. Folketrygdfondet raised its stake in Novo Nordisk A/S by 13.2% in the second quarter. Folketrygdfondet now owns 6,914,192 shares of the company’s stock valued at $296,550,000 after buying an additional 803,608 shares during the last quarter. River Road Asset Management LLC raised its stake in shares of Novo Nordisk A/S by 101.3% in the second quarter. River Road Asset Management LLC now owns 1,120,310 shares of the company’s stock worth $48,050,000 after purchasing an additional 563,729 shares during the last quarter. Nationwide Fund Advisors purchased a new position in shares of Novo Nordisk A/S in the second quarter worth about $21,031,000. Fisher Asset Management LLC raised its stake in shares of Novo Nordisk A/S by 3.7% in the third quarter. Fisher Asset Management LLC now owns 12,124,724 shares of the company’s stock worth $583,806,000 after purchasing an additional 433,727 shares during the last quarter. Finally, Orbimed Advisors LLC purchased a new position in shares of Novo Nordisk A/S in the third quarter worth about $15,890,000. 6.18% of the stock is currently owned by institutional investors.

Shares of Novo Nordisk A/S (NYSE:NVO) traded up $0.61 during mid-day trading on Monday, reaching $52.13. The company had a trading volume of 748,600 shares, compared to its average volume of 2,089,007. The stock has a market capitalization of $132,931.50, a PE ratio of 22.76, a P/E/G ratio of 3.07 and a beta of 0.63. Novo Nordisk A/S has a 52 week low of $32.83 and a 52 week high of $52.45.

Several research analysts have recently issued reports on the company. Morgan Stanley upgraded Novo Nordisk A/S from an “equal weight” rating to an “overweight” rating in a research note on Friday, December 1st. Bank of America upgraded Novo Nordisk A/S from a “neutral” rating to a “buy” rating in a research note on Wednesday, December 6th. BNP Paribas cut Novo Nordisk A/S from an “outperform” rating to a “neutral” rating in a research note on Monday, September 25th. Finally, Zacks Investment Research upgraded Novo Nordisk A/S from a “hold” rating to a “buy” rating and set a $55.00 price objective for the company in a research note on Tuesday, October 10th. Three research analysts have rated the stock with a sell rating, four have given a hold rating and two have issued a buy rating to the company. The stock currently has a consensus rating of “Hold” and a consensus target price of $55.00.

In related news, insider Eric S. Sprott purchased 50,000 shares of Novo Nordisk A/S stock in a transaction that occurred on Wednesday, November 8th. The stock was bought at an average cost of $8.34 per share, for a total transaction of $417,000.00.

TRADEMARK VIOLATION WARNING: “Foyston Gordon & Payne Inc Buys 56,941 Shares of Novo Nordisk A/S (NVO)” was first published by Watch List News and is the sole property of of Watch List News. If you are viewing this article on another website, it was illegally copied and reposted in violation of US & international copyright and trademark law. The original version of this article can be accessed at https://www.watchlistnews.com/foyston-gordon-payne-inc-buys-56941-shares-of-novo-nordisk-as-nvo/1757630.html.

About Novo Nordisk A/S

Novo Nordisk A/S is a global healthcare company engaged in diabetes care. The Company is also engaged in the discovery, development, manufacturing and marketing of pharmaceutical products. The Company operates through two business segments: diabetes and obesity care, and biopharmaceuticals. The Company’s diabetes and obesity care segment covers insulin, GLP-1, other protein-related products, such as glucagon, protein-related delivery systems and needles, and oral anti-diabetic drugs.

Want to see what other hedge funds are holding NVO? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Novo Nordisk A/S (NYSE:NVO).

Institutional Ownership by Quarter for Novo Nordisk A/S (NYSE:NVO)

Receive News & Ratings for Novo Nordisk A/S Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Novo Nordisk A/S and related companies with MarketBeat.com's FREE daily email newsletter.